SCHEMBL4964367

SCHEMBL4964367

Nc1cccc(O)c1NBr

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 4/20 0.48
TSHR P16473 3/20 0.48
CA2 P00918 6/20 0.36
ALDH1A1 P00352 5/20 0.36
TDP1 Q9NUW8 4/20 0.36
HSD17B10 Q99714 4/20 0.36
CA1 P00915 4/20 0.36
HPGD P15428 3/20 0.36
LMNA P02545 3/20 0.36
EGFR P00533 2/20 0.36
FYN P06241 2/20 0.36
MMP2 P08253 2/20 0.36
MMP9 P14780 2/20 0.36
RECQL P46063 2/20 0.36
ADAMTS4 O75173 1/20 0.36
MMP8 P22894 1/20 0.36
CA6 P23280 1/20 0.36
CDK2 P24941 1/20 0.36
MMP12 P39900 1/20 0.36
ADAMTS5 Q9UNA0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5570993 0.74 ALOX15 (0.44) ALOX15TSHRCA2ALDH1A1TDP1
SCHEMBL7254610 0.72 TSHR (0.43) ALOX15TSHRCA2HSD17B10CA1
SCHEMBL7083086 0.72 CXCR2 (0.49) ALOX15TSHRALDH1A1TDP1HSD17B10
SCHEMBL7250609 0.72 TSHR (0.43) ALOX15TSHRCA2ALDH1A1HSD17B10
SCHEMBL11022909 0.71 HDAC1 (0.49) ALOX15TSHRCA2ALDH1A1HSD17B10
SCHEMBL10934024 0.70 ALOX15 (0.40) ALOX15TSHRCA2ALDH1A1TDP1
SCHEMBL6806686 0.70 EP300 (0.42) ALOX15TSHRCA2ALDH1A1HSD17B10
SCHEMBL20810767 0.70 IDO1 (0.42) ALOX15TSHRALDH1A1HSD17B10HPGD
SCHEMBL7254561 0.69 CA12 (0.46) ALOX15TSHRCA2ALDH1A1HSD17B10
SCHEMBL7256858 0.69 ALDH1A1 (0.46) ALOX15TSHRCA2ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730140-B1 OPIOID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-06-25 EP disclosed
US-7288543-B2 For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage ELI LILLY AND COMPANY (US) 2007-10-30 US disclosed
US-20070179129-A1 Opioid receptor antagonists ELI LILLY AND COMPANY 2007-08-02 US disclosed
EP-1730140-A1 OPIOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-12-13 EP disclosed
WO-2005090337-A1 OPIOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179129-A1 Opioid receptor antagonists OPRK1, OPRM1, OPRL1 ALOX15 2720/4885TSHR 186/4885CA2 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.